Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
CRNX
Crinetics Pharmaceuticals, Inc.
Crinetics develops oral, nonpeptide small-molecule therapeutics (lead platform) targeting GPCRs and related pipelines.
|
$4.64B |
$49.16
-0.32%
|
|
ACAD
ACADIA Pharmaceuticals Inc.
ACADIA's portfolio includes Pimavanserin (NUPLAZID) and pipeline candidates that are small-molecule therapeutics, with additional small-molecule programs (e.g., ACP-204, ACP-711).
|
$4.60B |
$26.95
-1.14%
|
|
APGE
Apogee Therapeutics, Inc.
Directly develops and manufactures monoclonal antibody therapeutics (APG777, APG808, APG990).
|
$4.58B |
$75.36
-1.89%
|
|
IMVT
Immunovant, Inc.
IMVT-1402 and batoclimab are monoclonal antibodies targeting FcRn, aligning with monoclonal antibody therapeutics.
|
$4.53B |
$26.55
+2.13%
|
|
LNTH
Lantheus Holdings, Inc.
Directly produces radiopharmaceutical imaging agents and related therapies (e.g., PYLARIFY, DEFINITY) and maintains an expanding pipeline in this modality.
|
$4.53B |
$65.09
-2.22%
|
|
IEP
Icahn Enterprises L.P.
Pharma segment includes global drug development and commercialization activities (eg. Qsiva) typical of Large Cap Pharma companies.
|
$4.44B |
$7.72
-0.39%
|
|
OSIS
OSI Systems, Inc.
Patient Monitoring represents next-generation monitoring platforms and solutions within healthcare offerings.
|
$4.41B |
$263.01
+0.24%
|
|
AKRO
Akero Therapeutics, Inc.
EFX is a biologic drug with a specialized delivery formulation (pre-filled syringe/lyophilized product), placing it squarely in the Drug Delivery Platforms category.
|
$4.37B |
$54.67
+0.04%
|
|
SRRK
Scholar Rock Holding Corporation
Directly develops and markets monoclonal antibody therapeutics (apitegromab, SRK-439, SRK-181) across SMA, obesity/metabolic, and oncology.
|
$4.35B |
$43.62
-3.58%
|
|
CELC
Celcuity Inc.
Core asset gedatolisib targets oncology indications, placing Celcuity squarely in Biotech - Oncology.
|
$4.34B |
$100.90
-1.25%
|
|
WGS
GeneDx Holdings Corp.
Clinical lab chains providing genetic testing services.
|
$4.33B |
$142.03
-5.70%
|
|
PLXS
Plexus Corp.
Healthcare/Life Sciences end-market, with Plexus serving medical devices and related equipment through its engineering and manufacturing services.
|
$4.31B |
$153.35
-3.99%
|
|
NOVT
Novanta Inc.
Medical Devices & Biometrics aligning with their focus on medical devices and biometric sensing technologies.
|
$4.30B |
$120.49
+0.90%
|
|
TMDX
TransMedics Group, Inc.
TransMedics' Organ Care System (OCS) is a proprietary medical device platform for organ preservation and monitoring.
|
$4.20B |
$123.36
+0.17%
|
|
OSCR
Oscar Health, Inc.
Core product is health insurance plans via ACA marketplace and employer-based offerings, generating premium-based revenue.
|
$4.17B |
$15.68
-2.85%
|
|
CNO
CNO Financial Group, Inc.
Health insurance offerings (including Medicare Supplement) are a core segment.
|
$4.16B |
$42.97
+0.23%
|
|
BLTE
Belite Bio, Inc
Lead product Tinlarebant is an ophthalmic drug targeting retinal diseases (STGD1/GA).
|
$4.15B |
$147.55
+3.52%
|
|
VKTX
Viking Therapeutics, Inc.
VK2735 is a peptide-based dual GLP-1/GIP receptor agonist, the company's lead therapeutic.
|
$4.06B |
$35.85
-0.83%
|
|
LEGN
Legend Biotech Corporation
CARVYKTI is a CAR-T cell therapy and Legend Biotech's flagship product, representing its direct cell-therapy manufacturing and commercialization activity.
|
$4.04B |
$21.71
-1.36%
|
|
ALHC
Alignment Healthcare, Inc.
Alignment provides Medicare Advantage health insurance via its integrated health plan.
|
$3.98B |
$20.20
+0.47%
|
|
AMRX
Amneal Pharmaceuticals, Inc.
Main revenue driver is generic drugs in Affordable Medicines.
|
$3.91B |
$12.19
-2.17%
|
|
HAE
Haemonetics Corporation
Haemonetics manufactures medical devices and biometrics for hospital blood management and plasma processing.
|
$3.87B |
$80.40
|
|
TERN
Terns Pharmaceuticals, Inc.
The company is advancing oral small-molecule therapeutics (TERN-701 and TERN-601) for cancer and obesity, aligning with the 'Oral Small Molecule Therapeutics' investable theme.
|
$3.85B |
$42.45
-3.54%
|
|
ACLX
Arcellx, Inc.
Company's lead products are CAR-T cell therapies within oncology; direct product category is cell therapy.
|
$3.79B |
$66.47
-2.74%
|
|
LGND
Ligand Pharmaceuticals Incorporated
Captisol and NITRICIL are platform technologies Ligand licenses/sells to enable drug solubility and tunable dosing, constituting drug delivery platforms.
|
$3.78B |
$193.53
+0.34%
|
|
GPCR
Structure Therapeutics Inc.
Company focuses on developing oral small-molecule GPCR-targeted therapeutics, including lead GLP-1R agonist and other oral GPCR modulators.
|
$3.73B |
$61.87
-4.52%
|
|
NVST
Envista Holdings Corp
Envista directly manufactures dental equipment, including implants and aligners, a core product line.
|
$3.67B |
$21.94
-0.54%
|
|
ICUI
ICU Medical, Inc.
Infusion Systems is a major product line (Plum pumps, Medfusion/CADD integration) central to ICU Medical's revenue.
|
$3.65B |
$147.02
-0.68%
|
|
INSP
Inspire Medical Systems, Inc.
Inspire V is a neuromodulation device designed to treat obstructive sleep apnea, representing Inspire's core product category.
|
$3.53B |
$115.12
-3.47%
|
|
SWTX
SpringWorks Therapeutics, Inc.
SpringWorks specializes in oncology therapies using targeted small-molecule modalities (nirogacestat and mirdametinib).
|
$3.52B |
$46.99
|
|
CNTA
Centessa Pharmaceuticals plc
ORX750 is an orally administered, high-potency orexin receptor 2 (OX2R) agonist, fitting the 'Oral Small Molecule Therapeutics' category.
|
$3.51B |
$25.74
-1.57%
|
Showing page 8 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
